SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

SCYNEXIS ( (SCYX) ) has issued an update.

On March 31, 2026, SCYNEXIS held a conference call to discuss a strategic asset acquisition and broader corporate update, highlighting its purchase of global rights to SCY-770 from French biotech Poxel. The company detailed that SCY-770 is a well-characterized, Phase 2–ready AMPK activator for autosomal dominant polycystic kidney disease, supported by prior clinical exposure in other indications, orphan designation, an FDA-endorsed surrogate endpoint for accelerated approval, and intellectual property protection into 2042.

Management emphasized the deal terms, including $8 million upfront, up to $8 million in development milestones, and as much as $180 million in commercial milestones with no royalties owed, positioning the asset as a potential “pipeline-in-a-product” in ADPKD and possibly other metabolic diseases. SCYNEXIS also noted a recent $40 million PIPE financing that extends its cash runway to mid-2029, providing flexibility to advance SCY-770 into a planned Phase 2 trial starting in late 2026 and reinforcing its strategic shift toward high-value rare disease opportunities alongside ongoing antifungal and partnership-related revenue optionality.

The most recent analyst rating on (SCYX) stock is a Hold with a $0.81 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

Spark’s Take on SCYX Stock

According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.

Overall score reflects a balance between improved balance-sheet strength and funding visibility (low leverage and new financing) versus still-weak operating fundamentals (losses, negative free cash flow, and highly volatile revenue). Technical indicators are broadly neutral and do not materially offset the fundamental uncertainty, while valuation is constrained by the negative P/E.

To see Spark’s full report on SCYX stock, click here.

More about SCYNEXIS

SCYNEXIS, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe rare diseases. Its portfolio includes antifungal assets and SCY-770, a novel oral activator of AMP-activated protein kinase targeting autosomal dominant polycystic kidney disease, a multi-billion-dollar market with significant unmet medical need.

Average Trading Volume: 376,882

Technical Sentiment Signal: Sell

Current Market Cap: $35.27M

For an in-depth examination of SCYX stock, go to TipRanks’ Overview page.